Press Release|

SHL Medical reaffirms commitment to Taiwan

Shl Medical Loi Signing Moea Taiwan
SHL Medical strengthens its commitment to Taiwan by signing LOI for the fourth time

Tuesday, September 3, 2024 – Taipei, Taiwan – SHL Medical, a global leader in the self-injection space, today announced the signing of a Letter of Intent (LOI) with Taiwan’s Ministry of Economic Affairs (MOEA) for the fourth time. This renewed partnership reinforces SHL’s ongoing commitment to bolstering its operations in Taiwan with a significant investment of US$100 million over the next five years.

This strategic investment, aimed at strengthening SHL’s manufacturing capabilities to develop advanced innovative drug delivery technologies, will support the company’s long-term growth ambitions. The planned investment is also in line with Taiwan’s efforts to strengthen its position as a global hub for biotech and pharmaceutical industries.

“We are proud to continue our partnership with Taiwan, a key contributor to SHL’s global operations,” said Sebastian Feng, General Manager of SHL Medical Taiwan. “The signing highlights our confidence in Taiwan’s robust industrial infrastructure and the exceptional talents that drive our innovation forward.”

SHL’s investment will focus on enhancing its operations in Taiwan to meet the growing demand for self-injection devices. The company plans to allocate resources towards advanced automation, workforce development, workplace and equipment upgrades, as well as sustainable manufacturing practices. These initiatives align with SHL’s commitment to enhancing efficiency and its goal to reduce its carbon footprint across its operations.

The announcement follows a series of significant milestones, including the groundbreaking ceremony for its new Taoyuan-Nanmei site and the launch of its electronic vehicle.

“We believe that our continued investment in Taiwan not only supports our growth strategy but also contributes to the local economy and the advancement of the medical technology sector in the region,” Feng added. “We look forward to deepening our collaboration with the MOEA and furthering our shared vision of innovation and excellence.”

The signing took place at the 2024 Taiwan Business Alliance and Market Trend Forum and led by MOEA Minister, Dr. Jyh-Huei Kuo. Participants of the forum include AWS Taiwan and Hong Kong, Boston Consulting Group, Mogan Stanley Securities, SEMI, UBS Securities, and Quanta Computer Co., Ltd.

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  ​

In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.​

For additional information, visit www.shl-medical.com

Media contact: info@shl-medical.com

Share:

Related News

ZUG, Switzerland, NOV 21, 2024 — SHL Medical, a world leader in self-injection solutions, today announced plans to establish SHL Advantec – a dynamic sub-group dedicated to providing tooling and automation solutions to the healthcare sector and other industries. The establishment of SHL Advantec is part of SHL Medical’s ambitious expansion strategy and ongoing commitment…